Skip to main content
Erschienen in: Journal of Cancer Survivorship 3/2018

17.02.2018

The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source

verfasst von: Yvonne L. Eaglehouse, Stephanie Shao, Wenyaw Chan, Derek Brown, Janna Manjelievskaia, Craig D. Shriver, Kangmin Zhu

Erschienen in: Journal of Cancer Survivorship | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigates transition rates between breast cancer diagnosis, recurrence, and death by insurance benefit type and care source in U.S. Military Health System (MHS).

Methods

The MHS data repository and central cancer registry linked data were used to identify women aged 40–64 with histologically confirmed breast cancer between 2003 and 2007. Three-state continuous time Markov models were used to estimate transition rates and transition rate ratios (TRRs) by TRICARE benefit type (Prime or non-Prime) and care source (direct, purchased, or both), adjusted for demographic, tumor, and treatment variables.

Results

Analyses included 2668 women with transitions from diagnosis to recurrence (n = 832), recurrence to death (n = 79), and diagnosis to death without recurrence (n = 91). Compared to women with Prime within each care source, women with non-Prime using both care sources had higher transition rates (TRR 1.47, 95% CI 1.03, 2.10). Compared to those using direct care within each benefit type, women utilizing both care sources with non-Prime had higher transition rates (TRR 1.86, 95% CI 1.11, 3.13), while women with Prime utilizing purchased care had lower transition rates (TRR 0.82, 95% CI 0.68, 0.98).

Conclusions

In the MHS, women with non-Prime benefit plans compared to Prime had higher transition rates along the breast cancer continuum among both care source users. Purchased care users had lower transition rates than direct care users among Prime beneficiaries.

Implications for Cancer Survivors

Benefit plan and care source may be associated with breast cancer progression. Further research is needed to demonstrate differences in survivorship.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014;106(10). Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014;106(10).
2.
Zurück zum Zitat Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Mell LK, et al. The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol. 2015;117(2):393–9. Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Mell LK, et al. The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol. 2015;117(2):393–9.
3.
4.
8.
Zurück zum Zitat Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care. 2000;38(7):705–18.CrossRefPubMed Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care. 2000;38(7):705–18.CrossRefPubMed
10.
11.
Zurück zum Zitat Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167–72.CrossRefPubMed Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167–72.CrossRefPubMed
12.
Zurück zum Zitat Li YP, Chan W. Analysis of longitudinal multinomial outcome data. Biometrical journal Biometrische Zeitschrift. 2006;48(2):319–26. Li YP, Chan W. Analysis of longitudinal multinomial outcome data. Biometrical journal Biometrische Zeitschrift. 2006;48(2):319–26.
16.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
17.
Zurück zum Zitat American Joint Committee on Cancer. Breast. In: Eds. F.L. Greene, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al., editors. AJCC Cancer Staging Manual. Sixth Edition ed. United States of America: Springer; 2002. p. 223–40. American Joint Committee on Cancer. Breast. In: Eds. F.L. Greene, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al., editors. AJCC Cancer Staging Manual. Sixth Edition ed. United States of America: Springer; 2002. p. 223–40.
18.
Zurück zum Zitat Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(2):213–20.CrossRef Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(2):213–20.CrossRef
30.
Zurück zum Zitat National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2017. www.nccn.org. Accessed: 6 April 2017. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2017. www.​nccn.​org. Accessed: 6 April 2017.
Metadaten
Titel
The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source
verfasst von
Yvonne L. Eaglehouse
Stephanie Shao
Wenyaw Chan
Derek Brown
Janna Manjelievskaia
Craig D. Shriver
Kangmin Zhu
Publikationsdatum
17.02.2018
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 3/2018
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-018-0680-1

Weitere Artikel der Ausgabe 3/2018

Journal of Cancer Survivorship 3/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.